Low-dose "metronomic chemotherapy" with oral cyclophosphamide and methotrexate in metastatic breast cancer: A case report of extraordinarily prolonged clinical benefit

ecancermedicalscience

Volumn 6, Issue 1, 2012, Pages

  Masci, G ^a   Losurdo, A ^a   Gandini, C ^a   Garassino, I ^a   Di Tommaso, L ^a   Torrisi, R ^a   Zuradelli, M ^a   Santoro, A ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CA 15-3 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; TAMOXIFEN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER REGRESSION; CASE REPORT; CHEMOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; METRONOMIC CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84869406989     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2012.275     Document Type: Article

References (10)

1. Colleoni M, Rocca A, Sandri MT et al (2001) Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumour activity and correlation with vascular endothelial growth factor levels Ann Oncol 13 73-80 DOI: 10.1093/annonc/mdf013
2. Pasquier E, Kavallaris M, Andrè N (2010) Metronomic chemotherapy: new rationale for new directions Clin Oncol 7 455-65
3. Colleoni M, Orlando L, Sanna G et al (2006) Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumour activity and biological effects Ann Oncol 17(2) 232-8 DOI: 10.1093/annonc/mdj066 (Pubitemid 43160111)
4. Wong NS, Buckman RA, Clemons M et al (2010) Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response J Clin Oncol 28 723-30 DOI: 10.1200/JCO.2009.24.0143
5. Bottini A, Generali D, Brizzi MP et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primarysystemic treatment in elderly breast cancer patients J Clin Oncol 24 3623-8 DOI: 10.1200/JCO.2005.04.5773 PMID: 16877730 (Pubitemid 46630536)
6. Orlando L, Cardillo A, Ghisini R et al (2006) Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer BMC Cancer 15(6) 225 DOI: 10.1186/1471-2407-6- 225
7. Dellapasqua S, Bertolini F, Bagnardi V et al (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer J Clin Oncol 26(30) 4899-905 DOI: 10.1200/JCO.2008.17.4789 PMID: 18794539
8. Munoz R, Shaked Y, Bertolini F et al (2005) Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy The Breast 14 466-79 DOI: 10.1016/j.breast.2005.08.026 PMID: 16199161 (Pubitemid 41683568)
9. Browder T, Butterfield CE, Kraling BM et al (2000) Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60 1878-86 PMID: 10766175 (Pubitemid 30207647)
10. Curtis RE, Boice JD Jr, Storvall M et al (1992) Risk of leukemia after chemotherapy and radiation treatment for breast cancer N Engl J Med 326 1745-51 DOI: 10.1056/NEJM199206253262605 PMID: 1594016